Trial Profile
Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism; Stroke; Transient ischaemic attacks
- Focus Therapeutic Use
- Acronyms DARING-AF
- 16 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 15 Feb 2016 New trial record